Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBITDA (2016 - 2025)

Historic EBITDA for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to -$6.6 million.

  • Usana Health Sciences' EBITDA fell 13790.77% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 8015.67%. This contributed to the annual value of $33.1 million for FY2024, which is 4738.39% down from last year.
  • Usana Health Sciences' EBITDA amounted to -$6.6 million in Q3 2025, which was down 13790.77% from $13.8 million recorded in Q2 2025.
  • Usana Health Sciences' EBITDA's 5-year high stood at $41.8 million during Q3 2021, with a 5-year trough of -$6.6 million in Q3 2025.
  • In the last 5 years, Usana Health Sciences' EBITDA had a median value of $13.8 million in 2025 and averaged $15.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 11885.54% in 2023, then plummeted by 13790.77% in 2025.
  • Quarter analysis of 5 years shows Usana Health Sciences' EBITDA stood at $26.8 million in 2021, then decreased by 25.38% to $20.0 million in 2022, then rose by 16.43% to $23.3 million in 2023, then plummeted by 119.26% to -$4.5 million in 2024, then crashed by 47.14% to -$6.6 million in 2025.
  • Its EBITDA was -$6.6 million in Q3 2025, compared to $13.8 million in Q2 2025 and $9.3 million in Q1 2025.